The Technical Analyst
Select Language :
Altimmune Inc [ALT]

Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology

Altimmune Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Altimmune Inc is listed at the NASDAQ Exchange

-3.76% $11.26

Last updated: 3 jul 2022 - 19:20

TimeZone: America/New_York


FUNDAMENTALS
MarketCap: 486.65 mill
EPS: -2.39
P/E: 0.000
Earnings Date: Aug 08, 2022
SharesOutstanding: 43.22 mill
Avg Daily Volume: 1.304 mill
RATING 2022-07-01
B+
Neutral
RATINGDETAILS
Rating CashFlow: Strong Buy
Return On Equity: Sell
Return On Asset: Neutral
DE: Neutral
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
4/201/212/213/214/211/22
Revenue
Gr.Profitn/an/an/an/a
Ebit
Asset
Debtn/a
DISCOUNTED CASH FLOW VALUE
$18.68
(65.92%) $7.42
Date: 2022-07-03
True Range Average
+/- $0.999
( +/- 8.87%)
Range: 10.26 - 12.26
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2022-06-30 Garg Vipin K Sell 3 007 Common Stock, par value $0.0001
2022-06-29 Roberts M Scot Sell 5 462 Stock Options (option to buy)
2022-06-29 Roberts M Scot Sell 5 462 Common Stock, par value $0.0001
2022-06-29 Roberts M Scot Buy 5 462 Common Stock, par value $0.0001
2022-06-27 Roberts M Scot Sell 11 769 Stock Options (option to buy)
INSIDER POWER
41.52
Last 100 transactions
Buy: 2 730 937 | Sell: 1 274 483

Forecast: 16:00 - $11.26

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $11.26
Forecast 2: 16:00 - $11.26
Forecast 3: 16:00 - $11.26
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $11.26 (-3.76% )
Volume 1.581 mill
Avg. Vol. 1.304 mill
% of Avg. Vol 121.26 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Altimmune Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Altimmune Inc

RSI

Intraday RSI14 chart for Altimmune Inc

Last 10 Buy & Sell Signals For ALT

15 Signals | Accuracy: 33.33% | Accuracy Buy: 37.50% | Accuracy Sell: 28.57%

Avg return buy: -0.34 % | Avg return sell: 0.59 %

$1 invested is now $0.97 or -2.71% since 30-06-22

Date Signal @ Closed %
Jun 30 - 09:30sell$11.66$11.58 @ Jun 30 - 12:41-0.69%
Jun 30 - 09:29buy$11.77$11.66 @ Jun 30 - 09:30-0.93%
The Live Chart for Altimmune Inc
Profile picture for
            Altimmune Inc

ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.

Last 10 Buy Signals
Date Signal @
BNTUSDJul 3 - 19:180.483
ZRXUSDJul 3 - 19:180.297
UBQUSDJul 3 - 19:180.0337
ETCUSDJul 3 - 19:1814.79
DOGEUSDJul 3 - 19:17$0.0670
ADXUSDJul 3 - 19:170.143
XLMUSDJul 3 - 19:160.109
PPTUSDJul 3 - 19:150.115
NXTUSDJul 3 - 19:150.0034
XRPUSDJul 3 - 19:130.320

Stock Peers

Company Price Change
ALT11.26-3.76%
ARAY1.920-2.04%
GTHX5.174.66%
JNCE3.02-0.33%
KMDA4.45-1.33%
NVCT11.997.05%
SMLR28.671.74%
STRO5.250.77%
TKNO8.16-2.86%
TRDA12.00-1.48%
XOMA20.84-6.46%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.